plerixafor has been researched along with olaparib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, XL; Du, CW; Guo, JF; Wu, JF; Wu, NQ; Xie, XF; Zhang, GL | 1 |
2 other study(ies) available for plerixafor and olaparib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Topics: Cell Line, Tumor; DNA Damage; Humans; Phthalazines; Poly (ADP-Ribose) Polymerase-1; Receptors, CXCR4; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2022 |